2.74

3.86% -0.11

After Hours: 2.50 -0.24 -8.76%

Silexion Therapeutics Corp (SLXN)

Overview News Price History Discussions Forecast

Silexion Therapeutics Corp stock is traded at $2.74, with a volume of 10,506. It is down -3.86% in the last 24 hours and down -41.33% over the past month. Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.

Previous Close:

$2.85

Open:

$2.81

24h Volume:

10,506

Relative Volume:

0.02

Market Cap:

$2.91M

Revenue:

Net Income/Loss:

$-11.91M

P/E Ratio:

-0.309

EPS:

-8.8661

Net Cash Flow:

$-10.83M

1W Performance:

+7.45%

1M Performance:

-41.33%

6M Performance:

-86.95%

1Y Performance:

-97.76%

1-Day Range:

$2.64

$2.81

1-Week Range:

$2.54

$2.85

52-Week Range:

$2.31

$223.60

Silexion Therapeutics Corp Stock (SLXN) Company Profile

Name

Silexion Therapeutics Corp

Sector

Healthcare (1094)

Industry

Biotechnology (615)

Phone

972-8-6286005

Address

12 ABBA HILLEL ROAD, RAMAT GAN

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

SLXN's Discussions on Twitter

Compare SLXN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLXN Silexion Therapeutics Corp	2.74	3.03M	0	-11.91M	-10.83M	-8.8661
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Silexion Therapeutics Corp Stock (SLXN) Latest News

04:02 AM

Price to earnings forward of Silexion Therapeutics Corp – NASDAQ:SLXN - TradingView

04:02 AM

10:01 AM

Enterprise value to EBITDA forward of Silexion Therapeutics Corp – BOATS:SLXN - TradingView

10:01 AM

Jul 03, 2026

Silexion Therapeutics (SLXN) price target decreased by 33.33% to 6.12 - MSN

Jul 03, 2026

Jun 28, 2026

SLXN Q1 2026 Earnings: EPS Beat Highlights Narrower-than-Expected Loss Amid Development StageFinancial Summary - dars.gov.et

Jun 28, 2026

Jun 26, 2026

Price to sales forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView

Jun 26, 2026

Price to earnings forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Silexion Therapeutics Corp – BOATS:SLXNW - TradingView

Jun 26, 2026

Jun 24, 2026

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - Sahm

Jun 24, 2026

Silexion Therapeutics Warrants (SLXNW) Hold Flat at $0.03 as Range TightensComposite Profile - dars.gov.et

Jun 24, 2026

Form 13D/A Silexion Therapeutics Corp For: 23 June By Investing.com - Investing.com Australia

Jun 24, 2026

Jun 23, 2026

Silexion Therapeutics Says Germany Approves Phase 2/3 Trial of SIL204 in Pancreatic Cancer - marketscreener.com

Jun 23, 2026

Silexion Therapeutics Receives BfArM Approval to Initiate Phase 2/3 SIL204 Trial in Germany - Quiver Quantitative

Jun 23, 2026

Jun 22, 2026

[EFFECT] Silexion Therapeutics Corp SEC Filing - Stock Titan

Jun 22, 2026

SLXN Q1 2026 Earnings: Solid EPS Beat Highlights Cost Discipline Amid Pre-Revenue StageEarnings Risk Report - dars.gov.et

Jun 22, 2026

Jun 20, 2026

Silexion Therapeutics (SLXN) Slides 5.86% as Shares Approach Key Support at $2.59Oversold Bounce Ideas - dars.gov.et

Jun 20, 2026

Jun 19, 2026